Breaking News, Collaborations & Alliances

Bridge Biotherapeutics and HitGen Team Up for Oncology Drug Discovery

Enter a joint research agreement to accelerate the discovery of new drug candidates for an FIC novel cancer therapeutics program.

Author Image

By: Charlie Sternberg

Associate Editor

Bridge Biotherapeutics, a clinical-stage biotechnology company, has formed a strategic alliance with HitGen Inc., a leading Chinese drug discovery platform company, to accelerate the development of novel anticancer drug candidates. The collaboration builds upon the success of initial hit finding and identification work utilizing HitGen’s DNA-encoded library (DEL) technology.   Bridge Biotherapeutics aims to expand its oncology portfolio, currently focused on EGFR inhibitors for lung canc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters